CEO Total Pay
$29.0M
FY2021 Summary Compensation, well above median
The CEO earned $29.0M in FY2021 against median worker pay of $65,759 · Chemicals & Pharmaceuticals.
Data updated August 2026
Subscribe to Endo International plc CEO pay filing updates (RSS)
Latest filing FY2021. This company's newest DEF 14A on file is for FY2021, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
A component-level pay breakdown is not reported in Endo International plc's structured SEC pay-ratio disclosure. See our methodology →
Endo International plc disclosed 441:1 CEO-to-worker pay and $29.0M CEO total in FY2021. the CEO earned 441× the median employee ($65,759) in FY2021.
Median employee $65,759 (PAR-MED); HIGH · PEAK stamps put about 441 median-wage years per CEO year.
CEO Total Pay
$29.0M
FY2021 Summary Compensation, well above median
Pay Ratio
441:1
Outlier, top decile
Endo International plc disclosed 441:1 CEO-to-worker pay and $29.0M CEO total in FY2021. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Endo International plc's $29.0M CEO total is above the $7.9M industry median CEO pay.
Endo International plc stamps HIGH · PEAK · PAR-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Read our methodology - how this data is sourced, computed, and verified. Endo International plc disclosed 441:1 CEO-to-worker pay and $29.0M CEO total in FY2021.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps HIGH · PEAK · PAR-MED.
ABS(ceo_total_comp) peer at $28.8M (Δ $159K lighter vs Endo International plc); EXTREME · PAR-MED vs this page's HIGH · PEAK · PAR-MED.
ABS(ceo_total_comp) peer at $28.8M (Δ $162K lighter vs Endo International plc); EXTREME · LOW-MED vs this page's HIGH · PEAK · PAR-MED.
ABS(ceo_total_comp) peer at $29.2M (Δ $162K heavier vs Endo International plc); HIGH · PAR-MED vs this page's HIGH · PEAK · PAR-MED.
ABS(ceo_total_comp) peer at $28.8M (Δ $201K lighter vs Endo International plc); MEGA · HIGH-MED vs this page's HIGH · PEAK · PAR-MED.
Endo International plc stamps HIGH · PEAK · PAR-MED inside SIC 28 - open the industry median board after the ABS peers.
See where HIGH · PEAK packages sit on the national leaderboard after reading Endo International plc.
Endo International plc's PEAK CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.